Aligos Therapeutics (ALGS) Competitors $9.37 -0.83 (-8.14%) Closing price 04:00 PM EasternExtended Trading$9.31 -0.06 (-0.64%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. ACB, RNAC, CADL, MNPR, NMRA, LXEO, AVIR, ENGN, PRQR, and ALLOShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Aurora Cannabis (ACB), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), Monopar Therapeutics (MNPR), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), Atea Pharmaceuticals (AVIR), enGene (ENGN), ProQR Therapeutics (PRQR), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Its Competitors Aurora Cannabis Cartesian Therapeutics Candel Therapeutics Monopar Therapeutics Neumora Therapeutics Lexeo Therapeutics Atea Pharmaceuticals enGene ProQR Therapeutics Allogene Therapeutics Aurora Cannabis (NASDAQ:ACB) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation. Which has preferable earnings and valuation, ACB or ALGS? Aurora Cannabis has higher revenue and earnings than Aligos Therapeutics. Aurora Cannabis is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$246.72M1.14$1.63M-$0.19-26.16Aligos Therapeutics$3.94M14.63-$131.21M-$19.79-0.47 Is ACB or ALGS more profitable? Aurora Cannabis has a net margin of -5.66% compared to Aligos Therapeutics' net margin of -2,337.24%. Aurora Cannabis' return on equity of -1.49% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis-5.66% -1.49% -1.06% Aligos Therapeutics -2,337.24%-22.41%-12.09% Does the media prefer ACB or ALGS? In the previous week, Aligos Therapeutics had 2 more articles in the media than Aurora Cannabis. MarketBeat recorded 6 mentions for Aligos Therapeutics and 4 mentions for Aurora Cannabis. Aligos Therapeutics' average media sentiment score of 1.05 beat Aurora Cannabis' score of 0.73 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ACB or ALGS? Aligos Therapeutics has a consensus target price of $50.00, suggesting a potential upside of 433.62%. Given Aligos Therapeutics' higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ACB or ALGS? Aurora Cannabis has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500. Do institutionals and insiders have more ownership in ACB or ALGS? 47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAligos Therapeutics beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.63M$3.10B$5.74B$10.24BDividend YieldN/A2.32%5.69%4.59%P/E Ratio-0.4721.3874.9326.41Price / Sales14.63244.04457.2789.16Price / CashN/A44.4425.8129.91Price / Book-1.259.6413.256.28Net Income-$131.21M-$53.20M$3.29B$270.38M7 Day Performance-15.66%0.44%0.47%2.70%1 Month Performance21.69%4.26%4.60%5.99%1 Year Performance-36.69%9.43%73.42%25.94% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics3.9816 of 5 stars$9.37-8.1%$50.00+433.6%-31.1%$57.63M$3.94M-0.4790Positive NewsAnalyst ForecastACBAurora Cannabis0.4782 of 5 stars$4.84-1.4%N/A-16.0%$277.19M$246.72M-25.471,130RNACCartesian Therapeutics2.2953 of 5 stars$10.19-4.2%$40.00+292.5%-42.2%$276.66M$38.91M-0.1964Positive NewsCADLCandel Therapeutics2.3851 of 5 stars$5.10+2.0%$20.00+292.2%-31.7%$274.48M$120K-7.3960Positive NewsMNPRMonopar Therapeutics3.3031 of 5 stars$41.48-6.2%$69.57+67.7%+1,175.1%$272.77MN/A-12.4610News CoverageAnalyst ForecastGap UpNMRANeumora Therapeutics2.9078 of 5 stars$1.66-1.2%$7.14+330.3%-86.5%$272.07MN/A-1.06108Positive NewsLXEOLexeo Therapeutics2.6155 of 5 stars$5.25+4.6%$15.33+192.1%-46.4%$271.09M$650K-1.6158Positive NewsAVIRAtea Pharmaceuticals2.0764 of 5 stars$3.25-3.6%$6.00+84.6%-18.9%$267.43MN/A-2.0270Short Interest ↑ENGNenGene2.8385 of 5 stars$5.43+4.8%$23.29+328.8%-14.6%$264.73MN/A-3.2931Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionPRQRProQR Therapeutics2.6367 of 5 stars$2.33-4.9%$8.00+243.3%+18.4%$257.77M$20.46M-5.07180News CoveragePositive NewsShort Interest ↑ALLOAllogene Therapeutics2.8489 of 5 stars$1.14-0.9%$8.44+640.7%-61.8%$255.16M$20K-1.03310Analyst Downgrade Related Companies and Tools Related Companies Aurora Cannabis Competitors Cartesian Therapeutics Competitors Candel Therapeutics Competitors Monopar Therapeutics Competitors Neumora Therapeutics Competitors Lexeo Therapeutics Competitors Atea Pharmaceuticals Competitors enGene Competitors ProQR Therapeutics Competitors Allogene Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
